Composition comprising HMSs/HMOs and use thereof
The application relates to synthetic compositions containing one or more human milk mono- or oligosaccharides for treating non-infectious diarrhoea.
1 . One or more human milk monosaccharides (HMSs), one or more human milk oligosaccharides (HMOs), or a mixture thereof for the prophylaxis or treatment of non-infectious diarrhoea in a human.
2 . One or more HMSs, one or more HMOs, or a mixture thereof according to claim 1 , wherein the human is an irritable bowel syndrome patient, lactose intolerant patient and/or a patient having undergone antibiotic treatment.
3 . One or more HMSs, one or more HMOs, or a mixture thereof according to claim 1 effective to increase (i) the abundance, particularly the relative abundance, of bifidobacteria, and/or (ii) the beta-galactosidase activity, in the gastrointestinal tract of the human.
4 . One or more HMSs, one or more HMOs, or a mixture thereof according to claim 3 , wherein the bifidobacteria are those of the phylogenetic Bifidobacterium adolescentis group.
5 . One or more HMSs, one or more HMOs, or a mixture thereof according to claim 4 , wherein the bifidobacterium of the phylogenetic Bifidobacterium adolescentis group is Bifidobacterium pseudocatenulatum and/or Bifidobacterium adolescentis.
6 . One or more HMOs according to claim 1 , wherein the HMO is a fucosylated or a non-fucosylated neutral HMO.
7 . One or more HMOs according to claim 1 , wherein the HMO is 2′-FL, 3-FL, DFL, LNnT, LNT, 3′-SL, 6 0 ′-SL or LNFP-I, or a mixture thereof.
8 . The mixture of HMOs according to claim 6 comprising 2′-FL and LNnT or LNT or both.
9 . A synthetic composition for the prophylaxis or treatment of non-infectious diarrhoea in a human, the composition comprising an effective amount of a human milk monosaccharide (HMS) or a human milk oligosaccharide (HMO).
10 . The synthetic composition of claim 9 , wherein the human is an irritable bowel syndrome patient, lactose intolerant patient and/or a patient having undergone antibiotic treatment.
11 . The synthetic composition of claim 9 , comprising an amount of the HMS or HMO effective to increase (i) the abundance, particularly the relative abundance, of bifidobacteria, and/or (ii) the beta-galactosidase activity, in the gastrointestinal tract of the human.
12 . The synthetic composition of claim 11 , wherein the bifidobacteria are those of the phylogenetic Bifidobacterium adolescentis group.
13 . The synthetic composition of claim 12 , wherein the bifidobacterium of the phylogenetic Bifidobacterium adolescentis group is Bifidobacterium pseudocatenulatum and/or Bifidobacterium adolescentis.
14 . The synthetic composition of claim 9 , wherein the HMO is a fucosylated or a non-fucosylated neutral HMO.
15 . The synthetic composition of claim 9 , wherein the HMO is 2′-FL, 3-FL, DFL, LNnT, LNT, 3′-SL, 6′-SL or LNFP-I, or a mixture thereof.
16 . The synthetic composition of claim 14 , wherein the HMO is a mixture of a 2′-FL and LNnT or LNT or both.
17 . The synthetic composition of claim 9 , wherein the amount of the HMS or HMO is in the range of about 1 g to about 15 g.
18 . A method for the prophylaxis or treatment of non-infectious diarrhoea in a human, the method comprising administering to the human an effective amount of human milk monosaccharide (HMS) or human milk oligosaccharide (HMO).
19 . The method of claim 18 , wherein the human is an irritable bowel syndrome patient, lactose intolerant patient, and/or a patient having undergone antibiotic treatment.
20 . The method of claim 18 , wherein the amount of the HMS or HMO is effective to increase (i) the abundance, particularly the relative abundance, of bifidobacteria, and/or (ii) the beta-galactosidase activity, in the gastrointestinal tract of the human.
21 . The method of claim 18 , wherein the bifidobacteria are those of the phylogenetic Bifidobacterium adolescentis group.
22 . The method of claim 21 , wherein the bifidobacterium of the phylogenetic Bifidobacterium adolescentis group is Bifidobacterium pseudocatenulatum and/or Bifidobacterium adolescentis.
23 . The method of claim 18 , wherein the HMO is a fucosylated or a non-fucosylated neutral HMO.
24 . The method of claim 18 , wherein the HMO is 2′-FL, 3-FL, DFL, LNnT, LNT, 3′-SL, 6′-SL or LNFP-I, or a mixture thereof.
25 . The method of claim 23 , wherein the HMO is a mixture of a 2′-FL and LNnT or LNT or both.
26 . The method of claim 18 , wherein the human has intestinal dysbiosis and/or an impaired mucosal barrier.
27 . The method of claim 18 , wherein the human is administered a daily dose of the HMS or HMO of about 1 g to about 15 g.